Business Context and Reporting Period
This Form 6-K filing by Nova Measuring Instruments Ltd. (Nova) is dated June 14, 2017. The report serves as an amendment to Proposal No. 3 in the Proxy Statement for the Annual General Meeting of Shareholders scheduled for June 22, 2017. The filing details revised employment terms for Mr. Eitan Oppenhaim, the President and Chief Executive Officer.
Key Financial Metrics
The filing does not provide current period financial statements, revenue, profit, cash flow, or liquidity metrics for 2017. However, it references historical performance:
- 2016 Revenue: $163.9 million (record level).
- 2016 Growth: Represented the 4th consecutive year of revenue growth.
- 2016 Net Income: Record non-GAAP net income.
Material Changes and Executive Compensation
The primary material change disclosed is the amendment to the CEO's employment terms, approved by the Compensation Committee and Board of Directors. The proposed changes include:
- Salary Increase: Monthly salary increased from NIS 101,000 to NIS 120,000.
- Equity Grant (Effective July 1, 2017):
- Options: 70,000 options vesting over 4 years (25% annually). Term is 7 years. Exercise price based on the 30-day average closing price on NASDAQ prior to grant.
- Restricted Share Units (RSUs): 30,000 RSUs vesting over 3 years (33% annually), contingent on performance targets. Unvested portions may carry forward to the third vesting date if the Company achieves an average annual return on equity (ROE) of at least 10% over the previous three years.
Management justified these terms based on Mr. Oppenhaim's performance, the successful implementation of the ReVera acquisition, customer diversification, and alignment with the Company's Compensation Policy adopted in August 2016.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, specific risk factors, or contingencies beyond the standard conditions of the equity vesting schedule. The outlook is implicitly positive, citing record financial performance in 2016 and continued growth drivers such as organic and inorganic expansion.
Key Facts for Investor Verification
- Verify the final vote outcome of the amended Proposal No. 3 at the June 22, 2017 Annual General Meeting.
- Confirm the actual grant date and exercise price of the 70,000 options once the 30-day trading period concludes prior to July 1, 2017.
- Monitor the Company's ability to meet the 10% average annual ROE threshold required for the carry-forward vesting of RSUs.
- Review the full Proxy Statement filed on May 18, 2017, for context on the original proposal and other shareholder matters.